@article {Dayal2020.04.07.20053272, author = {Devi Dayal and Saniya Gupta}, title = {Connecting BCG Vaccination and COVID-19: Additional Data}, elocation-id = {2020.04.07.20053272}, year = {2020}, doi = {10.1101/2020.04.07.20053272}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The reasons for a wide variation in severity of coronavirus disease 2019 (COVID-19) across the affected countries of the world are not known. Two recent studies have suggested a link between the BCG vaccination policy and the morbidity and mortality due to COVID-19. In the present study we compared the impact of COVID-19 in terms of case fatality rates (CFR) between countries with high disease burden and those with BCG revaccination policies presuming that revaccination practices would have provided added protection to the population against severe COVID-19. We found a significant difference in the CFR between the two groups of countries. Our data further supports the view that universal BCG vaccination has a protective effect on the course of COVID-19 probably preventing progression to severe disease and death. Clinical trials of BCG vaccine are urgently needed to establish its beneficial role in COVID-19 as suggested by the epidemiological data, especially in countries without a universal BCG vaccination policy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding received for any aspect of the submitted workAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes all data will be made available}, URL = {https://www.medrxiv.org/content/early/2020/04/08/2020.04.07.20053272}, eprint = {https://www.medrxiv.org/content/early/2020/04/08/2020.04.07.20053272.full.pdf}, journal = {medRxiv} }